ID

31948

Description

Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01023256

Link

https://clinicaltrials.gov/show/NCT01023256

Keywords

Versions (1)
  1. 10/8/18 10/8/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

October 8, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Rheumatoid Arthritis NCT01023256

English

Eligibility Rheumatoid Arthritis NCT01023256

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
rheumatoid arthritis (ra) per revised 1987 acr criteria
Description

Rheumatoid Arthritis

Data type

boolean

Alias
UMLS CUI [1]
C0003873
active ra: ≥3 swollen and 3 tender joints with at least 1 swollen joint in the hand, excluding the pip joint
Description

Rheumatoid Arthritis | Swollen joint count | Tender joint count | Hand joint swollen Quantity | Exception Proximal interphalangeal joint

Data type

boolean

Alias
UMLS CUI [1]
C0003873
UMLS CUI [2]
C0451521
UMLS CUI [3]
C0451530
UMLS CUI [4,1]
C0459470
UMLS CUI [4,2]
C0038999
UMLS CUI [4,3]
C1265611
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0932508
crp > 5.0 mg/l (rf and anti-ccp seronegative); crp >2 mg/l (rf and/or anti-ccp seropositive)
Description

C-reactive protein measurement | Rheumatoid Factor Seronegative | Anti-CCP Seronegative | Rheumatoid Factor Seropositive | Anti-CCP Seropositive

Data type

boolean

Alias
UMLS CUI [1]
C0201657
UMLS CUI [2,1]
C0035448
UMLS CUI [2,2]
C0521144
UMLS CUI [3,1]
C4318437
UMLS CUI [3,2]
C0521144
UMLS CUI [4,1]
C0035448
UMLS CUI [4,2]
C0521143
UMLS CUI [5,1]
C4318437
UMLS CUI [5,2]
C0521143
das28 ≤ 5.1
Description

Disease activity score das28

Data type

boolean

Alias
UMLS CUI [1]
C4481729
stable regimen of concomitant ra therapy (nsaids, steroids, non- biological dmards).
Description

Therapy Stable Rheumatoid Arthritis | NSAIDs | Steroids | Non-Biologic DMARDs

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0205360
UMLS CUI [1,3]
C0003873
UMLS CUI [2]
C0003211
UMLS CUI [3]
C0038317
UMLS CUI [4]
C4054347
negative ppd tuberculin skin test
Description

PPD skin test Negative

Data type

boolean

Alias
UMLS CUI [1,1]
C0041290
UMLS CUI [1,2]
C1513916
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous therapy with b or t cell depleting agents other than rituximab (e.g. campath). prior treatment with rituximab, tnf-inhibitors, other biologics (e.g. anti-il-1 therapy) and systemic immunosuppressive agents is allowed with a washout period.
Description

B-cell depletion therapy | T-cell depletion | Exception Rituximab | Campath | Rituximab With Washout Period allowed | TNF inhibitor With Washout Period allowed | Biological agents With Washout Period allowed | Interleukin-1 Receptor Antagonist With Washout Period allowed | Immunosuppressive Agents Systemic With Washout Period allowed

Data type

boolean

Alias
UMLS CUI [1]
C1171324
UMLS CUI [2]
C0677960
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0393022
UMLS CUI [4]
C0939276
UMLS CUI [5,1]
C0393022
UMLS CUI [5,2]
C0332287
UMLS CUI [5,3]
C1710661
UMLS CUI [5,4]
C0683607
UMLS CUI [6,1]
C4521709
UMLS CUI [6,2]
C0332287
UMLS CUI [6,3]
C1710661
UMLS CUI [6,4]
C0683607
UMLS CUI [7,1]
C0005515
UMLS CUI [7,2]
C0332287
UMLS CUI [7,3]
C1710661
UMLS CUI [7,4]
C0683607
UMLS CUI [8,1]
C3536785
UMLS CUI [8,2]
C0332287
UMLS CUI [8,3]
C1710661
UMLS CUI [8,4]
C0683607
UMLS CUI [9,1]
C0021081
UMLS CUI [9,2]
C0205373
UMLS CUI [9,3]
C0332287
UMLS CUI [9,4]
C1710661
UMLS CUI [9,5]
C0683607
any history of ongoing, significant or recurring infections
Description

Communicable Diseases | Recurrent infections

Data type

boolean

Alias
UMLS CUI [1]
C0009450
UMLS CUI [2]
C0239998
any active inflammatory diseases other than ra
Description

Inflammatory disorder | Exception Rheumatoid Arthritis

Data type

boolean

Alias
UMLS CUI [1]
C1290884
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0003873
treatment with a systemic investigational drug within 6 months prior to screening
Description

Investigational New Drugs Systemic

Data type

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C0205373
women of childbearing potential, unless receiving stable doses of methotrexate or leflunomide
Description

Childbearing Potential | Exception Methotrexate Dose Stable | Exception Leflunomide Dose Stable

Data type

boolean

Alias
UMLS CUI [1]
C3831118
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0025677
UMLS CUI [2,3]
C0178602
UMLS CUI [2,4]
C0205360
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0063041
UMLS CUI [3,3]
C0178602
UMLS CUI [3,4]
C0205360
significant cardiac or pulmonary disease (including methotrexate- associated lung toxicity)
Description

Heart Disease | Lung disease | Lung Toxicity Associated with Methotrexate

Data type

boolean

Alias
UMLS CUI [1]
C0018799
UMLS CUI [2]
C0024115
UMLS CUI [3,1]
C0024109
UMLS CUI [3,2]
C0600688
UMLS CUI [3,3]
C0332281
UMLS CUI [3,4]
C0025677
hepatic or renal insufficiency
Description

Hepatic Insufficiency | Renal Insufficiency

Data type

boolean

Alias
UMLS CUI [1]
C1306571
UMLS CUI [2]
C1565489
Back to the top of the page

Similar models

Eligibility Rheumatoid Arthritis NCT01023256

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Rheumatoid Arthritis
Item
rheumatoid arthritis (ra) per revised 1987 acr criteria
boolean
C0003873 (UMLS CUI [1])
Rheumatoid Arthritis | Swollen joint count | Tender joint count | Hand joint swollen Quantity | Exception Proximal interphalangeal joint
Item
active ra: ≥3 swollen and 3 tender joints with at least 1 swollen joint in the hand, excluding the pip joint
boolean
C0003873 (UMLS CUI [1])
C0451521 (UMLS CUI [2])
C0451530 (UMLS CUI [3])
C0459470 (UMLS CUI [4,1])
C0038999 (UMLS CUI [4,2])
C1265611 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0932508 (UMLS CUI [5,2])
C-reactive protein measurement | Rheumatoid Factor Seronegative | Anti-CCP Seronegative | Rheumatoid Factor Seropositive | Anti-CCP Seropositive
Item
crp > 5.0 mg/l (rf and anti-ccp seronegative); crp >2 mg/l (rf and/or anti-ccp seropositive)
boolean
C0201657 (UMLS CUI [1])
C0035448 (UMLS CUI [2,1])
C0521144 (UMLS CUI [2,2])
C4318437 (UMLS CUI [3,1])
C0521144 (UMLS CUI [3,2])
C0035448 (UMLS CUI [4,1])
C0521143 (UMLS CUI [4,2])
C4318437 (UMLS CUI [5,1])
C0521143 (UMLS CUI [5,2])
Disease activity score das28
Item
das28 ≤ 5.1
boolean
C4481729 (UMLS CUI [1])
Therapy Stable Rheumatoid Arthritis | NSAIDs | Steroids | Non-Biologic DMARDs
Item
stable regimen of concomitant ra therapy (nsaids, steroids, non- biological dmards).
boolean
C0087111 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0003873 (UMLS CUI [1,3])
C0003211 (UMLS CUI [2])
C0038317 (UMLS CUI [3])
C4054347 (UMLS CUI [4])
PPD skin test Negative
Item
negative ppd tuberculin skin test
boolean
C0041290 (UMLS CUI [1,1])
C1513916 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
B-cell depletion therapy | T-cell depletion | Exception Rituximab | Campath | Rituximab With Washout Period allowed | TNF inhibitor With Washout Period allowed | Biological agents With Washout Period allowed | Interleukin-1 Receptor Antagonist With Washout Period allowed | Immunosuppressive Agents Systemic With Washout Period allowed
Item
previous therapy with b or t cell depleting agents other than rituximab (e.g. campath). prior treatment with rituximab, tnf-inhibitors, other biologics (e.g. anti-il-1 therapy) and systemic immunosuppressive agents is allowed with a washout period.
boolean
C1171324 (UMLS CUI [1])
C0677960 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0393022 (UMLS CUI [3,2])
C0939276 (UMLS CUI [4])
C0393022 (UMLS CUI [5,1])
C0332287 (UMLS CUI [5,2])
C1710661 (UMLS CUI [5,3])
C0683607 (UMLS CUI [5,4])
C4521709 (UMLS CUI [6,1])
C0332287 (UMLS CUI [6,2])
C1710661 (UMLS CUI [6,3])
C0683607 (UMLS CUI [6,4])
C0005515 (UMLS CUI [7,1])
C0332287 (UMLS CUI [7,2])
C1710661 (UMLS CUI [7,3])
C0683607 (UMLS CUI [7,4])
C3536785 (UMLS CUI [8,1])
C0332287 (UMLS CUI [8,2])
C1710661 (UMLS CUI [8,3])
C0683607 (UMLS CUI [8,4])
C0021081 (UMLS CUI [9,1])
C0205373 (UMLS CUI [9,2])
C0332287 (UMLS CUI [9,3])
C1710661 (UMLS CUI [9,4])
C0683607 (UMLS CUI [9,5])
Communicable Diseases | Recurrent infections
Item
any history of ongoing, significant or recurring infections
boolean
C0009450 (UMLS CUI [1])
C0239998 (UMLS CUI [2])
Inflammatory disorder | Exception Rheumatoid Arthritis
Item
any active inflammatory diseases other than ra
boolean
C1290884 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0003873 (UMLS CUI [2,2])
Investigational New Drugs Systemic
Item
treatment with a systemic investigational drug within 6 months prior to screening
boolean
C0013230 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
Childbearing Potential | Exception Methotrexate Dose Stable | Exception Leflunomide Dose Stable
Item
women of childbearing potential, unless receiving stable doses of methotrexate or leflunomide
boolean
C3831118 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0025677 (UMLS CUI [2,2])
C0178602 (UMLS CUI [2,3])
C0205360 (UMLS CUI [2,4])
C1705847 (UMLS CUI [3,1])
C0063041 (UMLS CUI [3,2])
C0178602 (UMLS CUI [3,3])
C0205360 (UMLS CUI [3,4])
Heart Disease | Lung disease | Lung Toxicity Associated with Methotrexate
Item
significant cardiac or pulmonary disease (including methotrexate- associated lung toxicity)
boolean
C0018799 (UMLS CUI [1])
C0024115 (UMLS CUI [2])
C0024109 (UMLS CUI [3,1])
C0600688 (UMLS CUI [3,2])
C0332281 (UMLS CUI [3,3])
C0025677 (UMLS CUI [3,4])
Hepatic Insufficiency | Renal Insufficiency
Item
hepatic or renal insufficiency
boolean
C1306571 (UMLS CUI [1])
C1565489 (UMLS CUI [2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial